Home › Trials › NCT06121843

Evaluating a new treatment for relapsed and refractory multiple myeloma

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Phase 1 Interventional Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT06121843

This study is testing a new treatment combination for people with relapsed or hard-to-treat multiple myeloma to see if it is safe and effective.

Quick facts

PhasePhase 1
Study typeInterventional
Enrollment147 (estimated)
Ages18 Years and up
SexAll
SponsorJuno Therapeutics, Inc., a Bristol-Myers Squibb Company Industry-sponsored
Drugs / interventionsalnuctamab, elranatamab
Locations19 sites (Birmingham, Alabama and 18 other locations)
Trial IDNCT06121843 on ClinicalTrials.gov

What this trial studies

This study aims to determine the safety and tolerable dosage of BMS-986393 when used in combination with other treatments such as alnuctamab, mezigdomide, and iberdomide in patients suffering from relapsed and/or refractory multiple myeloma. Participants will be closely monitored to assess the effectiveness of these combinations and to ensure patient safety throughout the trial. The study is designed for individuals who have previously undergone multiple treatment regimens for their condition.

Who should consider this trial

Good fit: Ideal candidates are individuals with a history of relapsed and/or refractory multiple myeloma who have received at least one prior treatment regimen.

Not a fit: Patients with active central nervous system involvement of multiple myeloma or those with conditions that could interfere with data interpretation may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a new effective treatment option for patients with difficult-to-treat multiple myeloma.

How similar studies have performed: Other studies have shown promise with similar treatment combinations in multiple myeloma, indicating potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
* Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
* Eastern Cooperative Oncology Group performance status of 0-1.

Exclusion Criteria:

* Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
* Prior treatment with GPRC5D-targeting therapies.
* Other protocol-defined inclusion/exclusion criteria apply.

Where this trial is running

Birmingham, Alabama and 18 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Multiple MyelomaBMS-986393Relapsed Multiple MyelomaRefractory Multiple MyelomaFirst-in-humanAlnuctamabMezigdomideIberdomide
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.